Table 2 Histopathological findings after preoperative chemotherapy
From: Dedifferentiated parosteal osteosarcoma of the maxilla: a case report and review of the literature
Reference | Number of cases | Sites | Surgery | Preoperative chemotherapy | Postoperative chemotherapy | Response | Prognosis |
|---|---|---|---|---|---|---|---|
Bertoni et al. (2005) [3] | 6 | Humerus, femur, tibia | Resection | Details unknown | None | Grade II (50–89% necrosis: Huvos grading system) | NED: 4 DOD: 2 |
Sheth et al. (1996) [4] | 10 | Femur, tibia | En bloc excision | Intra-arterial cisplatin (dose range, 120–160 mg/m2), intravenously administered doxorubicin (dose range,60–90 mg/m2), 4.2 cycles (range, 2–12 cycles) | One of the following: ▪high-dose methotrexate ▪doxorubicin, dacarbazine ▪high-dose methotrexate, cisplatin ▪high-dose methotrexate, ifosfamide ▪high-dose methotrexate, doxorubicin, dacarbazine Doxorubicin, cisplatin | Good response: 4 (with > 90% necrosis of the high-grade component). Poor response: 6 (with < 90% necrosis of the high-grade component) | NED: 5 DOD: 5 |
Futani et al. (2001) [11] | 1 | Fibula | En bloc excision | Intravenously administered high-dose methotrexate (dose range, 9.5–11.4 g/m2), intra-arterial pirarubicin (dose range, 50–80 mg/m2), and dacarbazine (dose range, 400–600 mg/m2) three cycles | None | 90% necrosis | NED |